Hansa Biopharma AB
  • Hansa Biopharma AB
  • Contacts
  • Share:
  • Subscribe:
  • news.cision.com/
  • Hansa Biopharma AB/
  • Swedish Medical Products Agency approves Hansa Medical’s clinical Phase II-study application with IdeS/
  • IdeS vial

IdeS vial

Tue, May 06, 2014 08:00 CET

IdeS vial
Transplantation Orphan Drug enzyme kidney Rare Disease IdeS Sensitized Desensitization IgG-degrading enzyme of Streptococcus pyogenes IgG-degrading

Low resolution

Medium resolution

Original resolution

Contacts

  • Hansa Biopharma AB
    Scheelevägen 22 22363 Lund, Sweden
    +46 (0) 461 656 70
    http://www.hansabiopharma.com
    IR@hansabiopharma.com

Subscribe

Related Releases

Phase II IdeS-study initiated in Uppsala Wed, Jul 09, 2014 08:00 CET
Hansa Medical to present IdeS at the 2014 World Transplant Congress in San Francisco, July 27 Tue, Jul 01, 2014 08:00 CET
Hansa Medical’s rights issue oversubscribed Fri, Apr 11, 2014 08:30 CET
©Cision
Privacy statement | Cookies | About | Content Policy | Contact    Cision
©Cision Privacy statement Cookies About Content Policy Contact

   Cision